On September 21, 2017, Stanley Yarbro announced that from June 30, 2017 until July 14, 2017, he has unsuccessfully attempted to contact senior management of Calmare Therapeutics Incorporated to set up a meeting to discuss various aspects of the Company’s operations, financial structure, and strategy. Stanley Yarbro stated that on or above July 14, 2017, he has followed up with a letter to the Company’s management once again requesting a meeting with the Board of Directors to discuss the issues raised in the initial Schedule 13D including the longstanding underperformance and mismanagement of the Company. Stanley Yarbro also noted that the Company’s failure to timely file its Form 10-K for the period ending December 31, 2016 and its Form 10-Qs for the whole of 2017, as well as the financial status of the Company.